ASCO Annual Meeting

Videos

The ATHENA-MONO trial is investigating the use of rucaparib as front line maintenance treatment in ovarian cancer.

Expert: Consider Dose Intensity With PARP Inhibitors for Ovarian Cancer

Expanded glomerular filtration rate (GFR) testing in the United States could be one step toward minimizing disparities in renal formulas, Beumer said.

Expert: Treating Patients As Individuals Is Essential to Minimizing Disparities in Oncology

The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes. 

Glofitamab Shows Promise in Large B-Cell Lymphoma

Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.

Expert: Improving Disparities in Biomarker Testing Requires Involvement of Multiple Stakeholders

Articles

The treatment also significantly reduces the risk of progression or death and prolonged median PFS compared with fulvestrant in all individuals without prior chemotherapy, the analysis shows.

Study: Elacestrant Prolongs Progression-Free Survival for ER+/HER2- Breast Cancer

Although it has clear benefits when monitoring and managing cancer, Feinberg said more widespread use of circulating tumor DNA will take time.

Expert: Increasing Use of Circulating Tumor DNA in Oncology Will Take Time

Investigators report that the 2 individuals receiving the 120-mg dosage had 3 probable immune-related adverse events, which provides supportive evidence of immune activation.

ChemoCentryx Releases Phase 1 Data of CCX559, Consistent With Preclinical Results

Results from a phase 3b study showed that venetoclax combined with azacitidine or decitabine can safely be initiated in a US community-based outpatient setting.

Study: Venetoclax Plus Hypomethylating Agent Effective in Newly Diagnosed Acute Myeloid Leukemia, Safe in Outpatient Setting

Blinded independent central review analysis also adds confidence to the findings.

Subgroup Analysis in ATHENA-MONO Trial Shows Encouraging Results for Rucaparib in Ovarian Cancer

JZP458, a recombinant Erwinia-derived ASNase from a Pseudomonas fluorescens expression platform, was previously approved by the FDA for patients with ALL/LBL who had developed hypersensitivity to Escherichia coli (E. coli)–derived ASNase.